ABSTRACT: Siderophores are iron chelators secreted by bacteria to scavenge iron(III) from their surrounding environment. They possess their own internalization pathway that is sufficiently unselective to be hijacked, making them suitable for Trojan Horse strategy applications. A commercially available siderophore, deferoxamine B (DFO), was derivatized at the primary amine with carboxylic acids bearing different ligands to afford mono-and bidentate complexes with ruthenium as well as a RAPTA-like complex in which DFO is tethered to the coordinated arene ring. These compounds were tested for antibacterial activity against key ESKAPE pathogens, and antiproliferative studies against healthy (HEK-293) and tumoral (A2780) human cells were performed. Some of the complexes displayed interesting dual anticancer and antibacterial properties. Combining these two properties within a single compound is desirable as patients treated for cancer have a weakened ability for fighting infections.
■ INTRODUCTION
Since the discovery of penicillin in 1928, 1 a tremendous number of antimicrobial drugs have been developed targeting bacteria (antibacterial), fungi (antifungal), viruses (antiviral), and parasites (antiparasitic). As a consequence, many common yet fatal illnesses such as pneumonia and tuberculosis have become less deadly. Infections were, for a time, no longer an ever present risk and the dangers linked to surgery or childbirth were drastically reduced. However, due to the intensive worldwide use of antibiotics, especially in agriculture, bacteria and other pathogens have evolved to overcome the effect of these drugs. Antimicrobial resistance (AMR) is becoming increasingly problematic as the discovery of new antibiotic formats has slowed, and is now an issue of global importance. 2−5 With infections and infectious diseases remaining one of the major causes of death worldwide, 6 and the emergence of antibacterial resistance, the development of novel classes of antibacterial drugs is of the utmost importance.
Ruthenium(III) and ruthenium(II) drugs are prominent families of anticancer agents, developed in the quest to overcome platinum-based resistance. 7 At the forefront are NAMI-A, 8 KP1019, 9 and NKP-1339, 10 showing promising results in preclinical and phase I and I/II clinical trials. Ruthenium(II)−arene complexes such as RAPTA ([Ru(η 6 -arene)X 2 (PTA)], PTA = 1,3,5-triaza-7-phosphaadamantane) 11 or RAED (([Ru(η 6 -arene)(en)Cl] + , en = ethylenediamine) 12 show a wide range of promising anticancer properties. 13−15 Interestingly, RAPTA-C, arene = p-cymene, has also been investigated as a potential antimicrobial agent and displayed activity against different strains of bacteria. 16 Ruthenium(II)− arene complexes represent an interesting platform that can be easily structurally modified, and several clinical drugs such as kinase inhibitor staurosporine, 17 glutathione-S-transferase inhibitor ethacrynic acid, 18 antifungal agents, 19 or antibacterial quinolones 20, 21 have been coupled to them, either to augment their anticancer activity or to have dual-functioning drug candidates, being both antibacterial and anticancer agents. 20, 21 Coupling these two therapeutic effects is desirable in the clinics where patients treated for cancer often show weakened ability to fight infections. 22 Iron is an essential element for almost all organisms (animals, plants, and micro-organisms), being involved in electron transport and metabolic processes from photosynthesis to DNA biosynthesis. 23 This involvement in so many biological reactions makes it a vital element for the survival of living organisms. While animals can source iron from food, plants and microorganisms need to obtain it from their surrounding environment. The most common strategy is the use of ferric ion chelators as solubilizing agents. 24 This is achieved through the secretion of siderophores (literally "iron carriers"). These low molecular weight compounds (<1000 Da) possess an extremely high affinity for the Fe 3+ ion. 25 Siderophores are secreted by bacteria in response to an iron restriction to scavenge any Fe 3+ that can be found in the surrounding environment. Siderophores usually form hexadentate octahe-dral complexes with the ferric ion, coordinating through oxygen atoms of hydroxamates, catecholates, a-hydroxycarboxylates or their combination. 26 Despite being selective for ferrisiderophores, this transport system is unselective enough to induce internalization of exogenous siderophores produced by other bacteria, referred to as xeno-siderophores. 27, 28 Siderophores are vital for bacteria pathogenicity, not only through iron(III) binding. 29 Reversing the idea of using antibacterial drugs in tumor cells, a Trojan Horse strategy 30−35 can be applied to deliver anticancer compounds such as ruthenium(II)−arene complexes inside bacteria. Such a strategy takes advantage of the ironuptake mechanism of both Gram-positive and Gram-negative bacteria 36 to deliver antibiotic moieties directly to the cytoplasm to circumvent membrane-mediated AMR. 37 The Trojan Horse strategy takes inspiration from the naturally occurring sideromycins, 38 antibiotics that are covalently linked to siderophores. Based on the study of these sideromycins and their potential, the rational design of synthetic siderophoredrug conjugates was developed, taking advantage of the ability of bacteria to internalize siderophore derivatives. 30,32,39−41 Used in iron-chelation therapy to treat iron overload, 42 deferoxamine B (DFO, brand name Desferal) is the only commercially available clinically approved siderophore that is available on a gram scale, making it an interesting candidate for Trojan Horse applications. Several nonferric complexes of this siderophore have been reported. Al, 43 Cr, 44 and radioactive 45 derivatives were studied to investigate the coordination chemistry of this siderophore and the mechanism of ferrisiderophore uptake. DFO and other iron chelators have also been investigated as antimalarial agents acting by iron sequestration. 46−48 Therapeutically relevant studies have been performed on a gallium−DFO complex, which showed potent antibacterial properties against antibiotic-resistant P. aeruginosa. 49 The primary amine of DFO does not participate in the binding to iron and can therefore be functionalized without drastically interfering with the binding. Several synthetic conjugates of DFO and its analogs with antibiotic moieties have also been synthesized and showed antibacterial activity (Figure 1 ), although usually lower than the drug alone. 33, 50, 51 Derivatives of DFO with fluorophores have also been synthesized to study the mechanism of action of such Trojan Horse drugs. 52 Nonantibacterial drugs, such as DNA intercalators, have also been investigated. 53 It was found that such compounds degrade DNA through redox damage due to the iron.
Metal-based drugs such as RAPTA complexes have not previously been used as components of Trojan Horse antimicrobial drugs, despite the fact that they display some intrinsic antibacterial properties. Here, we describe the synthesis of conjugates of DFO with ruthenium(II)−arene fragments for potential dual antibacterial/anticancer drugs, and their cytotoxicity studies against human cancerous and healthy cells, as well as resistant and nonresistant bacteria strains. A series of ruthenium(II)−arene complexes modified with DFO, 3a−c, were prepared using the route presented in Scheme 1. Coupling of carboxylic acids with the primary amine of DFO was optimized from the adaption of a literature procedure. 54 A solution of carboxylic acid activated by carbonyldiimidazole (CDI) at 60°C in dimethylformamide (DMF) was added dropwise to a solution of DFO and triethylamine in dimethylsufloxide (DMSO), and the reaction mixture was stirred at 60°C and monitored by mass spectrometry (MS). Completion was reached in less than an hour for all ligands 2a−c (Scheme 1). After purification, they were all obtained in good yields (77−88%).
The ruthenium(II) complexes 3a−c were prepared in a single step from 2a−c by reaction with the dichloro(pcymene)ruthenium dimer in dry methanol under inert conditions over 1 h. The RAPTA-type complex 3d was prepared following a related reported procedure 55 using TBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate) as the coupling agent in the presence of diisopropylethylamine (DIPEA) in DMSO. Following purification, complexes 3a−d were obtained in moderate to good yields (57−82%).
All compounds were characterized by 1 H, 13 C{ 1 H}, and where applicable, 31 P NMR spectroscopy, ESI-MS, and elemental analysis. NMR spectra of 3a and 3b indicate the presence of several species, most notably for 3b (see Figures S11 and S12), the two chlorides initially bound to ruthenium being substituted by two oxygen atoms of DFO. Several different modes of coordination of DFO to the ruthenium center (through two of its three hydroxyl groups and one hydroxamate) are possible, hence the presence of several species. Although the use of protection groups such as an oxalate moiety could avoid this displacement, 55 it was found to be unnecessary since, upon addition of an equimolar solution of iron(III) chloride, both 3a and 3b mixtures gave only one compound with two chlorides bound to the ruthenium(II) center.
Complex 3a was obtained as one major product and several minor species. Complexation was assessed by positive ion ESI-MS and NMR spectroscopy. The aromatic protons of the pyridyl moiety shift from 8.61 (ortho to the nitrogen) and 7.53 (meta to the nitrogen) to 8.47 and 7.26 ppm, respectively (Δδ H ≈ 0.2 and 0.3 ppm). The singlet corresponding to the methylene group between the pyridyl and the amide also shifts to lower frequencies (Δδ H ≈ 0.4 ppm) and becomes a doublet, indicating the presence of several species. The 13 C{ 1 H} NMR spectrum shows modest changes following complexation to the ruthenium ion, the pyridyl carbons shifting to lower ppm (Δδ C ≈ 0.8 ppm). Upon addition of FeCl 3 , the ferrisiderophore ligand was found to rapidly detach from the ruthenium(II) center.
Similar changes were observed for 3b, where the aromatic protons shift to higher frequencies (Δδ H ≈ 0.2 ppm) and several peaks from the DFO become split. Complexation was assessed by 31 P NMR spectroscopy, where the presence of several species is shown by several peaks that shifted from −6.94 ppm (ligand 2b) to 24.0−26.0 ppm, corresponding to the dichloro form and different oxygen-coordinated species at higher frequencies. Upon addition of an equimolar solution of iron(III) chloride, only one peak in the 31 P NMR spectrum is observed at 24.9 ppm, corresponding to the dichloro species, which is also the only product observed by ESI-MS. Coordination of the ligand to the metal ion is also denoted by peaks in the 13 
C{
1 H} NMR spectrum corresponding to the quaternary carbon atoms covalently linked to the phosphorus, which shift to lower frequencies (Δδ C ≈ 1.5 ppm) and larger coupling constants (Δ 1 J ≈ 17 and 26 Hz), similar to values found in literature, 56 although the spectrum is complicated by the presence of several similar species. The amide linking DFO to the triphenylphosphine moiety also shifts to higher frequencies (Δδ C = 4.9 ppm).
In contrast to the 2a,b/3a,b pairs, the aromatic protons of ligand 2c all shift to lower field when coordinated to the ruthenium(II) center. The two doublets corresponding to the aromatics protons in the ortho position to the nitrogen atoms shift from 8. 65 H} NMR spectrum after coordination with the aromatic carbon atoms shifting to higher frequencies (Δδ C ≈0.3 to 3.9 ppm).
As the environment of the ruthenium center in 3d is close to that of its starting material (Scheme 2), coupling with DFO to afford 3d does not induce drastic changes in the NMR spectra, except for the addition of new peaks derived from the DFO moiety. The 1 H NMR spectrum presents peaks for both the DFO moiety and the RAPTA complex with very minor changes, and the peak in the 31 P NMR spectrum corresponding to the PTA moiety only shifts from −32.2 to −33.3 ppm.
The cytotoxicity of DFO, ligands 2a−c, and ruthenium(II) complexes 3a−d in the absence or presence of iron(III) was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay 57 against human ovarian carcinoma cell lines (A2780) and human embryonic kidney (HEK-293) cells (Table 1 ). The ferrisiderophore species were obtained by mixing equimolar DMSO solutions of the corresponding siderophore derivative with FeCl 3 . Comparison between this method and the separate synthesis and purification of the ferrisiderophore compounds was performed and shown to yield similar results. The cytotoxicities of cisplatin and RAPTA-C were evaluated as positive and negative controls, respectively. All compounds were predissolved in DMSO before being immediately diluted into the appropriate cell culture medium. Stability studies under pseudocell culture conditions of 100 mM NaCl in H 2 O and 5% DMSO were conducted on 3a−d over 72 h. The stability was monitored via ESI-MS or 1 H and 31 P NMR spectroscopy. All complexes showed good stability under these conditions except for 3b in absence of iron(III), where the arene ligand was displaced (see Figure S2 ). Notably, the ferrisiderophore analogue of 3b is stable under these conditions. Interestingly, introduction of iron(III) reduces the cytotoxicity of the compounds, presumably as the three hydroxyl groups of the siderophore are no longer free. This observation is apparent for DFO where, upon addition of iron(III), the cytotoxicity changes from the micromolar range (13 ± 6 and 4 ± 2 μM against A2780 and HEK-293, respectively) to inactive at the maximum dose tested. For potential therapeutic applications, the ferrisiderophore form would not only help to avoid unwanted toxicity, but ferrisiderophores are preferentially internalized in bacteria so this form facilitates targeting. In presence of iron(III), ligand 2c is the only ligand with an antiproliferative effect against the nontumorigenic HEK-293 cells.
Complexes 3b,c possess moderate cytotoxicity against the A2780 cell line. In presence of iron(III), 3b displays higher cytotoxicity against A2780 cells, contrary to the other compounds (33 ± 2 μM against 109 ± 6 μM in absence of iron(III)). This may be explained by the decoordination of DFO from the ruthenium ion, as its affinity for iron(III) is higher. A 7-fold selectivity toward A2780 cells is observed for 3b in the presence of iron(III), with IC 50 values of 33 ± 2 and >200 μM, which is higher than the 5-fold selectivity of cisplatin although the overall activity is lower. Despite being cytotoxic to healthy HEK-293 cells in its iron(III)-free form (IC 50 = 23 ± 1 μM), complex 3c is also selective for A2780 cell line in the presence of iron(III) (91 ± 10 μM versus >200 μM), although with a lower selectivity than 3b. Due to the structural similarity with 3b, complex 3a might be expected to follow the same trend, but the pyridyl ligand 2a was found to dissociate from the ruthenium center upon addition of iron(III). 3a shows no cytotoxicity against A2780 and HEK cells (IC 50 > 200 μM). Complex 3d is cytotoxic to both cell lines in its iron(III)-free form (107 ± 2 and 15 ± 2 μM against A2780 and HEK-293 cell lines, respectively) but inactive when iron(III) was added.
Contrary to previously described RAPTA complexes such as RAPTA-C, which possess low cytotoxicities with IC 50 values >200 μM, 11 complexes 3a−d are moderately cytotoxic against human cell lines. As they are structurally similar, cytotoxicity arises from the functionalization with DFO. Note that other RAPTA-type compounds modified with functional bioactive molecules at the coordinated arene ring are often cytotoxic. 40 ,58−60 The activity of both 3b and 3c is in the micromolar range, with IC 50 values 20 to 60 times higher than cisplatin, albeit comparable to other ruthenium(II) complexes bearing organic bioactive moieties 61, 62 or CAP ligands instead of the PTA moiety, 63 but with much higher selectivity toward cancerous cell lines. The cancer cell selectivity observed for 3b is higher than cisplatin and similar to ruthenium(II)-arene compounds bearing perfluorinated alkyl chains 64 that show promising in vivo antitumor effects. 65 All compounds were tested for activity against four of the key ESKAPE pathogens (S. aureus, K. pneumoniae, A. baumannii, and P. aeruginosa), 66 as well as E. coli and two fungi, C. albicans and C. neoformans. Inhibition of bacterial growth at a single concentration of 20 μM after 18 h of incubation was determined for 2a−c and 3a−d (Table 2) , as well as for some other ruthenium(II) arene complexes (Table S1 ). DFO itself and ligands 2a−c were found to be inactive, some even promoting bacterial growth, presumably as they help to deliver iron(III) to the organism. These data show which bacterial strains and fungi were more susceptible to internalize DFO, as they grow better in the presence of the siderophore, i.e. E. coli, P. aeruginosa, and C. neoformans. S. aureus growth was slightly inhibited by ligands 2a−c, possibly via iron(III) sequestration. K. pneumoniae, A. baumannii, and C. albicans growth showed no significant change when incubated with the compounds. The lack of toxicity of the ligand implies that any further activity found for ruthenium complexes 3a−d emanates from the ruthenium fragment. Surprisingly, the same trend was observed for complexes 3b− d, which all promoted the growth of E. coli and P. aeruginosa in the presence of iron(III), whereas modest growth inhibition 
a Values are given as the mean ± standard deviation (μM). (Table S1 ). Only one showed significant antibacterial activity against two species (S. aureus and C. neoformans), a derivative of RAPTA-C bearing a triphenylphosphine group instead of the PTA moiety. However, this compound was previously found to be quite toxic to HEK-293 cells, 56 probably due to its hydrophobicity, and is not suitable for antibacterial applications. This confirms the potential of 3b as an antibacterial, since it is structurally similar in the iron(III)-chelated form. Although ligands 2a−c showed susceptibility to C. neoformans, all ruthenium complexes promote the growth of this fungus. For several Trojan Horse drugs, it was shown that drug release and the use of cleavable linkers, triggered by phosphatase, esterase, 40 or reductase enzymes, 67 might be necessary for more potent activity. 68 The observed relatively low antibacterial activity observed for complexes 3a−d could be due to the stability of the linkers.
■ CONCLUDING REMARKS
DFO-ligand conjugates 2a−c and DFO-containing ruthenium complexes 3a−d were synthesized, and their antiproliferative activity was assessed against human cancerous and noncancerous cell lines. Complexes 3b and 3c display good cancer cell selectively, despite being less active than cisplatin. The growth inhibitions of several strains of key pathological bacterial strains by ligands 2a−c, complexes 3a−d, and some RAPTA-like complexes were also determined. Although only modest growth inhibition was observed, these compounds are an order of magnitude more active than ruthenium compounds modified with antibacterial/antifungal agents. 19, 21 Thus, the modification of ruthenium complexes with DFO, allowing it to be internalized in bacteria, appears to be a more successful approach, with both cytotoxicities and selectivity against cancerous cell lines and similar growth inhibition of different bacterial strains at ten times lower concentrations. Further studies could include the use of other naturally occurring or synthetic siderophores and an evaluation of the use of cleavable linkers.
■ EXPERIMENTAL SECTION Materials. RuCl 3 ·xH 2 O was purchased from Precious Metals Online. All other chemicals were purchased from Aldrich, Alfa Aesar, Acros, Abcam, and TCI chemicals and used without further purification. [Ru(p-cymene)Cl 2 ] 2 69 and [Ru(PTA)(μ-oxalato)(3-(4-methylcyclohexa-1,4-dien-1-yl)propionic acid)] 55 were prepared following literature procedures. Dichloromethane (DCM) was dried and degassed using a PureSolv solvent purification system (Innovative Technology, Inc.). Thin-layer chromatography was conducted on Merck 60 F254 TLC silica-gel-coated aluminum sheets and verified by a UV lamp at 254 nm and KMnO 4 staining. The compounds were purified via a Varian 971-FP flash chromatography system using prepackaged silica gels columns (Luknova). General Procedure for the Synthesis of DFO Derivatives 2a−c. A solution of deferoxamine mesylate (1.0 equiv) and TEA (3.0 equiv) in DMSO was heated at 60°C for 30 min. At the same time, a solution of carboxylic acid (1.2 equiv) and CDI (1.2 equiv) in DMF was heated at 60°C for 30 min. After 30 min, the solution of activated acid was added dropwise to the other solution, and the reaction mixture was stirred for 1 h at 60°C. The reaction was monitored by mass spectrometry and after completion, the solvent was evaporated, and the crude product was purified by flash column chromatography using a DCM/MeOH gradient (0−20% over 50 min) as eluent. Compound 3a. According to the general procedure, a solution of ligand 2a (0.02 g, 0.03 mmol, 1.0 equiv) and dichloro(p-cymene) ruthenium dimer (0.01 g, 0.03 mmol, 1.0 equiv) in methanol (10 mL) was stirred for 1 h. After completion, the solvent was evaporated and the crude product washed with DCM (3 × 10 mL) and acetone (3 × 10 mL) to afford pure product 3a as an orange powder (0.02 g, 0.02 mmol, 57%). Compound 3b. According to the general procedure, ligand 2b (0.05 g, 0.06 mmol, 1.0 equiv) and dichloro(p-cymene)ruthenium dimer (0.02 g, 0.06 mmol, 1.0 equiv) reacted in methanol (10 mL) for 1 h. After completion, diethyl ether (30 mL) was added, and the orange precipitate was washed several times with diethyl ether to afford pure product 3b as an orange powder (0.05 g, 0.04 mmol, 83%). 1 Compound 3d. According to a reported procedure, 55 [Ru(μ-oxalato)(3-(4-methylcyclohexa-1,4-dien-1-yl)propionic acid) (PTA)] (0.08 g, 0.15 mmol, 1.0 equiv) was stirred in DMSO (2 mL) with TBTU (0.05 g, 0.15 mmol, 1.0 equiv) and DIPEA (0.14 mL, 0.75 mmol, 5.0 equiv) for 30 min. Then a solution of deferoxamine mesylate (0.10 g, 0.15 mmol, 1.0 equiv) in DMSO (1 mL) was added dropwise, and the reaction was monitored by MS. After 10 min, the reaction was deemed complete, acetone (40 mL) was added, and the precipitate was filtered, washed twice with acetone, and dried in vacuo to afford pure product 3d as a yellow powder (0.11 g, 0.10 mmol, 70% Discrepancies in the elemental analysis values were found to be higher than the acceptable 0.4% range and are therefore not reported. Similar observations have been made for other DFO conjugates reported in the literature. 70 This is due to the high coordination ability of the siderophore that apparently collects metal ions during measurements. NMR and MS data indicate good purity of all compounds.
Stability Studies. The stability of complexes 3a−d and their iron(III) derivatives in pseudocell culture conditions was assessed in aqueous 100 mM NaCl and 5% DMSO for 72 h at 298 K and monitored via 1 H and 31 P NMR when possible, and ESI-MS(+) otherwise.
Cell Culture and in Vitro Antiproliferative Activity. The human ovarian carcinoma (A2780) cell line was obtained from the European Collection of Cell Cultures. The human embryonic kidney (HEK-293) cell line was obtained from ATCC (Sigma, Buchs, Switzerland). Penicillin streptomycin, RPMI 1640 GlutaMAX (where RPMI = Roswell Park Memorial Institute), and DMEM GlutaMAX media (where DMEM = Dulbecco's modified Eagle medium) were obtained from Life Technologies, and fetal bovine serum (FBS) was obtained from Sigma. The cells were cultured in RPMI 1640 GlutaMAX (A2780) and DMEM GlutaMAX (HEK-293) media containing 10% heat-inactivated FBS and 1% penicillin streptomycin at 37°C and CO 2 (5%). The cytotoxicity was determined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. 57 Cells were seeded in flat-bottomed 96-well plates as a suspension in a prepared medium (100 μL aliquots and approximately 4300 cells/well) and preincubated for 24 h. Stock solutions of compounds were prepared in DMSO and were rapidly diluted in a medium. The solutions were sequentially diluted to give a final DMSO concentration of 0.5% and a final compound concentration range (0−200 μM). Cisplatin was tested as a positive control (0−10 μM). RAPTA-C was tested as a negative control (200 μM). The compounds were added to the preincubated 96-well plates in 100 μL aliquots, and the plates were incubated for 72 h. MTT (20 μL, 5 mg/mL in Dulbecco's phosphate buffered saline) was added to the cells, and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals, formed by the mitochondrial dehydrogenase activity of vital cells, were dissolved in DMSO (100 μL/well). The absorbance of the resulting solutions, directly proportional to the number of surviving cells, was quantified at 590 nm using a microplate reader. The percentage of surviving cells was calculated from the absorbance of wells corresponding to the untreated control cells. The reported IC 50 values (Table 1) are based on the means from three independent experiments, each comprising four tests per concentration level.
Antibacterial Assay. All bacteria were cultured in Cation-adjusted Mueller Hinton broth (CAMHB) at 37°C overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at 37°C for 1.5−3 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by OD 600 ) and then added to each well of the compound containing plates, giving a cell density of 5 × 10 5 CFU/mL and a total volume of 50 μL. All of the plates were covered and incubated at 37°C for 18 h without shaking. Inhibition of bacterial growth was determined measuring absorbance at 600 nm (OD 600 ) using a Tecan M1000 Pro monochromator plate reader. The percentage of growth inhibition was calculated for each well using the negative control (media only) and positive control (bacteria without inhibitors) on the same plate as references. The significance of the inhibition values was determined by modified Z-scores, calculated using the median and MAD of the samples (no controls) on the same plate. Samples with inhibition value above 80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed as actives. Samples with inhibition values between 50−80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed as partial actives. Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively. The antibiotics were provided in four concentrations, with two above and two below its MIC value, and plated into the first 8 wells of column 23 of the 384-well NBS plates. The quality control (QC) of the assays was determined by the antimicrobial controls and the Z′-factor (using positive and negative controls). Each plate was deemed to fulfill the quality criteria (pass QC), if the Z′-factor was above 0.4, and the antimicrobial standards showed full range of activity, with full growth inhibition at their highest concentration, and no growth inhibition at their lowest concentration.
Antifungal Assay. Fungi strains were cultured for 3 days on yeast extract−peptone dextrose (YPD) agar at 30°C. A yeast suspension of 1 × 10 6 to 5 × 10 6 CFU/mL (as determined by OD 530 ) was prepared from five colonies. The suspension was subsequently diluted and added to each well of the compound-containing plates giving a final cell density of fungi suspension of 2.5 × 10 3 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 35°C for 24 h without shaking. Growth inhibition of C. albicans was determined by measuring absorbance at 530 nm (OD 530 ), while the growth inhibition of C. neoformans was determined measuring the difference in absorbance between 600 and 570 nm (OD 600−570) , after the addition of resazurin (0.001% final concentration) and incubation at 35°C for additional 2 h. The absorbance was measured using a Biotek Synergy HTX plate reader. The percentage of growth inhibition was calculated for each well, using the negative control (media only) and positive control (fungi without inhibitors) on the same plate. The significance of the inhibition values was determined by modified Z-scores, calculated using the median and MAD of the samples (no controls) on the same plate. Samples with inhibition value above 80% and ZScore above 2.5 for either replicate (n = 2 on different plates) were classed as actives. Samples with inhibition values between 50−80% and Z-score above 2.5 for either replicate (n = 2 on different plates) were classed as partial actives. Fluconazole was used as a positive fungal inhibitor standard for C. albicans and C. neoformans. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.organomet.7b00885.
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